Phio Pharmaceuticals Corp. — Investor Relations & Filings
Filings indexed
857
across all filing types
Latest filing
2026-04-08
Regulatory Filings
Country
US
United States of America
Listing
US
PHIO
Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company developing immuno-oncology therapeutics. The company's proprietary INTASYL technology is a self-delivering RNA interference (RNAi) platform that utilizes small interfering RNA (siRNA) to silence genes. This process is designed to enhance the ability of the body's immune cells to recognize and kill cancer cells. Phio's development pipeline is focused on treatments for solid tumors, with key initiatives in cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its lead clinical compound is PH-762.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-04-08 | English | |
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-03-30 | English | |
| Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | 2026-02-23 | English | |
| 8-K - PHIO PHARMACEUTICALS CORP. (0001533040) (Filer) | 2026-02-18 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-02-10 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
14 filings
| |||||
| 33847768 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-04-08 | English | ||
| 33087316 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-03-30 | English | ||
| 32828377 | Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company | 2026-02-23 | English | ||
| 32893507 | 8-K - PHIO PHARMACEUTICALS CORP. (0001533040) (Filer) | 2026-02-18 | English | ||
| 30422182 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 19423381 | 8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer) | 2026-02-10 | English | ||
| 30422106 | 4 Filing | 2026-02-06 | English | ||
| 30422104 | 4 Filing | 2026-02-06 | English | ||
| 30422074 | 4 Filing | 2026-02-06 | English | ||
| 30422072 | 4 Filing | 2026-02-06 | English | ||
| 30422071 | 4 Filing | 2026-02-06 | English | ||
| 30422066 | 4 Filing | 2026-02-06 | English | ||
| 30422205 | 8-K Filing | 2026-01-20 | English | ||
| 12500297 | Director's Dealing 2026 | 2026-01-02 | English | ||
|
2025
1 filing
| |||||
| 12500300 | Director's Dealing 2025 | 2025-12-29 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Phio Pharmaceuticals Corp. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35112/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35112 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35112 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35112 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35112}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Phio Pharmaceuticals Corp. (id: 35112)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.